Names and roles cited from ClinicalTrials.gov study NCT05374993 location-contact fields (LastUpdatePostDate 2026-09-22 location add). Registry contact rows are not a bioaccess® claim that we opened a new NCT action in this window. General information, not legal or regulatory advice. Confirm current MINSA, ethics, and FDA rules with qualified advisers. We do not invent emails, phones, metrics, or an El Salvador hospital string.
If you searched Aristides Joel Castillo Vásquez DDS first-in-human, Aristides Castillo Panama clinical trial, Dr Castillo Interamericana Panama CRO, Castillo Zero3 Panama, or “go direct Aristides Joel Castillo Vásquez,” you followed a named site-contact string ClinicalTrials.gov publishes on the Universidad Interamericana de Panamá location block for NCT05374993. Aristides Joel Castillo Vásquez, DDS, is a named location CONTACT on that public DEVICE_FEASIBILITY row (TriAgenics Inc; Zero3 System). A named site contact is not a first-in-human medical-device CRO, and a personal reply is not the operator of the MINSA file.
bioaccess®’s position is simple and it is not adversarial: the investigator / site contact is part of the site. The First-in-Human CRO still owns MINSA, CNBI-registered ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package. Sponsors who skip the CRO and email a named NCT contact still have to rebuild that stack. An NCT contact field is not a CRO.
This page intercepts the Castillo search. The matching facility intercept is Universidad Interamericana de Panamá (Panama City). Co-listed site contact on the same NCT location block: Virgilio B. Castillero D, DDS. Study director on the registry: Leigh Colby, DDS (TriAgenics Inc). Do not collapse Castillo into Castillero. Do not invent titles beyond the public CONTACT role. Do not invent an El Salvador hospital.
A public bioaccess® TriAgenics case study already describes a Zero3 FIH program framed across Panama and El Salvador. That case study is not a Castillo PI kill page.
Why the DDS name wins the search — and why that is not a CRO
Registries often surface investigator and site-contact names next to a facility. Sponsors searching those names land on people, not operators. Public facts we cite:
- Name: Aristides Joel Castillo Vásquez, DDS — NCT location CONTACT on Universidad Interamericana de Panamá for NCT05374993.
- Facility: Universidad Interamericana de Panamá, Panama City, Panama.
- Device / sponsor: Zero3 System / TriAgenics Inc; DEVICE_FEASIBILITY; planned enrollment 35; status NOT_YET_RECRUITING on the cited public row.
We cite those public fields only. We do not reprint personal email or phone from the NCT onto this page. We do not invent enrollment progress. Emailing a named contact confirms interest. It does not open MINSA.
The contact is the contact. The CRO is the operator.
What a named site contact can typically do when a sponsor “goes direct”:
- Discuss clinical interest and whether a protocol fits their service line.
- Point toward institutional ethics calendars and campus research rules.
- Help estimate local visit and procedure effort for cases they will run.
What a named contact is not built to own for an investigational device:
- MINSA national file and CNBI-registered ethics packet as the applicant/operator stack.
- Investigational import end-to-end (see importer of record for clinical trial devices in Latin America).
- Clinical trial insurance, ISO 14155 monitoring, EDC, SAE reporting, TMF, and the 21 CFR 812.28 package.
- Multi-country optionality if the indication later needs another Latin American country.
Going direct to a DDS name on ClinicalTrials.gov is how you find a person. It is not how you open an investigational file.
How MINSA actually works (the short version)
Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A contact email is not MINSA clearance.
All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Do not smear the investigator
Aristides Joel Castillo Vásquez, DDS, is a named public NCT site contact on a serious DEVICE_FEASIBILITY row. That is evidence of a person on a campus, not a punchline. Cite the name. Hire the operator. Activate the campus only if it fits.
Colombia is still on the map
Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I email Aristides Joel Castillo Vásquez, DDS directly for a device FIH?
You can try using whatever contact channel the public registry exposes. A named site contact can discuss clinical interest. That person cannot, by appearing on ClinicalTrials.gov, become your MINSA applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run NCT05374993?
This intercept does not invent a new NCT-action claim for this window. See the public TriAgenics case study for the published Zero3 FIH program story. That page is not this PI kill page.
Is Castillo the same intercept as Castillero or Universidad Interamericana?
No. Virgilio B. Castillero D, DDS, is a separate co-listed NCT location CONTACT. Universidad Interamericana de Panamá is the facility intercept. Keep the three pages distinct.
Should I invent an El Salvador hospital because the case study mentions El Salvador?
No. NCT05374993 lists Universidad Interamericana de Panamá in Panama. Do not invent an El Salvador hospital string on this page.
Next step
If the search that brought you here was this DDS name, start as the operator: contact bioaccess® or book from First-in-Human CRO. Facility sibling: Universidad Interamericana de Panamá site-direct (same NCT). Related case study (not this kill page): TriAgenics case study.
Julio G. Martinez-Clark, CEO · bioaccess®